Rad AI Analysis Points to Siemens Lead and Rising Chinese Competition in Photon-Counting CT

According to a recent LinkedIn post from Rad AI, the company has published a comprehensive, AI-generated analysis of the photon-counting computed tomography (PCCT) competitive landscape. The post indicates that Siemens currently holds more than 80% market share with over 1,000 NAEOTOM Alpha installations, while GE Healthcare’s Photonova Spectra system is described as still awaiting FDA clearance and facing underlying silicon physics challenges. Canon’s PCCT offering is characterized as being under development, and Philips is portrayed as having made a strategic decision to prioritize its Verida spectral CT platform instead of PCCT, reportedly arguing that PCCT adds complexity and has not yet transitioned from research to routine clinical practice. The analysis also notes the emergence of two domestic PCCT systems in China—Neusoft’s NeuViz P10 and United Imaging’s uCT Ultima—suggesting that Siemens’ historical monopoly may be weakening.

The LinkedIn post highlights that the report covers detector material trade-offs, FDA status by vendor, market projections, bonding technologies, and strategic implications for buyers and investors. For investors, this content points to several potential themes: Siemens’ early-mover advantage in PCCT and entrenched installed base; regulatory and technical risks for GE as it seeks FDA clearance and scales silicon-based solutions; execution and timing risk for Canon as a late entrant; and strategic opportunity versus risk for Philips in focusing on spectral energy-integrating detector (EID) CT rather than PCCT. The mention of two Chinese PCCT platforms underscores growing competition from domestic Chinese manufacturers, which could pressure pricing and accelerate technological diffusion globally if these vendors gain regulatory approvals outside China. The use of Rad AI’s own AI agent to generate a detailed market report may also signal the company’s ambition to position itself as an analytics and decision-support provider in medical imaging, potentially enhancing its visibility and relevance to industry stakeholders and investors tracking innovation and competitive dynamics in advanced CT technology.